Related Experiment Video
Updated: Mar 6, 2026

09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
12.1K
Association of Changes in Activity Patterns With Brain Atrophy and Disability Progression in People With Multiple
Kathryn C Fitzgerald1, Muraleetharan Sanjayan1, Blake E Dewey1
1Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD; and.
Neurology
|March 4, 2026
Summary
Decreased daytime activity in people with multiple sclerosis (PwMS) predicts worsening disability and brain atrophy. Accelerometry offers a sensitive, noninvasive method to track these subtle, early changes in disease progression.
Area of Science:
- Neurology
- Biomedical Engineering
- Rehabilitation Science
Background:
- Multiple Sclerosis (MS) is a chronic neurological disease characterized by progressive disability.
- Subtle changes in daily activity may indicate early disease progression in people with MS (PwMS).
- Objective monitoring of physical activity is crucial for understanding disease trajectory.
Purpose of the Study:
- To determine if accelerometry can detect subtle, longitudinal changes in disability among PwMS.
- To assess the relationship between accelerometry-derived activity measures and brain atrophy and disability worsening at an individual level.
Main Methods:
- Longitudinal study of 238 PwMS (aged ≥40) over 3 years, with annual brain MRI and quarterly accelerometer use.
- Accelerometry measured total activity, sedentary time, and circadian rhythm parameters.
- Disability worsening assessed via Expanded Disability Status Scale-plus (EDSS+); brain atrophy via whole-brain segmentation.
Main Results:
- A 2.0% annual decline in total activity was observed.
- Within-person decreases in daytime activity (8:00-14:00) significantly predicted higher risk of EDSS+-confirmed disability progression.
- Declines in morning activity correlated with increased whole-brain, deep gray matter, and thalamic volume loss.
Conclusions:
- Reductions in daytime activity patterns precede clinical disability worsening and brain atrophy in PwMS.
- Longitudinal accelerometry shows promise as a sensitive, noninvasive biomarker for detecting subclinical disease progression in MS.
- Further research is needed to establish thresholds and responsiveness for accelerometry measures.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K

